Caffeine and neurodegenerative disorders
Abstract
Prevalence of the neurodegenerative disorders is progressively increasing. This demands search for the approaches to modifying their progression. Caffeine is one of the most widely consumed psychoactive substances globally. Its effects are dose-dependent, and among caffeine’s mechanisms of action the main one is non-specific antagonism to adenosine receptors. In this review, current knowledge on use of caffeine in such neurodegenerative disorders as Parkinson’s disease, Alzheimer’s disease, Huntington's disease, and amyotrophic lateral sclerosis is summarized.
About the Authors
Yu. A. Selivyorstov
Scientific Centre of Neurology
Russian Federation
Russian Federation
M. E. Babin
Moscow State University n.a. M. V. Lomonosov
Russian Federation
Russian Federation
References
1. Ершова М. В., Полевая Е. В., Сухоруков В. С., Иванова-Смоленская И.А., Иллариошкин С. Н. Цитохимическая оценка нарушений клеточной энергетики при нейродегенеративных заболеваниях. В сборнике «Болезнь Паркинсона и расстройства движений. Руководство для врачей по материалам I Национального конгресса по болезни Паркинсона и расстройствам движений (с международным участием)». М., 2008: 43-47.
2. Некрасов Е.Д., Лебедева О. С., Васина Е. М., Богомазова А. Н., Честков И. В., Киселев С. Л., Лагарькова М. А., Клюшников С. А., Илларошкин С. Н., Гривенников И. А. Платформа для изучения болезни Гентингтона на основе индуцированных плюрипотентных стволовых клеток. Анналы клинической и экспериментальной неврологии. 2012; 6 (4): 30-34.
3. Селиверстов Ю. А., Селиверстова Е. В., Коновалов Р. Н., Клюшников С. А., Кротенкова М. В., Иллариошкин С. Н. Клиниконейровизуализационный анализ болезни Гентингтона с использованием функциональной магнитно-резонансной томографии покоя. Неврологический журнал. 2015; 20 (3): 11-21.
4. Федотова Е. Ю., Чечеткин А. О., Иллариошкин С. Н. Возможности транскраниальной сонографии в диагностике экстрапирамидных заболеваний. Анналы клинической и экспериментальной неврологии. 2010; 4 (4): 43-50.
5. Ainhoa Onatibia-Astibia, Rafael Franco, Eva Martfnez-Pinilla. Health benefits of methylxanthines in neurodegenerative disease. Mol Nutr Food Res. 2016.
6. Arendash GW, Mori T, Cao C, Mamcarz M, Runfeldt M, Dickson A, Rezai-Zadeh K, Tane J, Citron BA, Lin X, Echeverria V, Potter H. Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice. Journal of Alzheimer's disease. 2009; 17: 661-80.
7. Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology. 2003; 60 (5): 790-795.
8. Ascherio A, Weisskopf MG, O'Reilly EJ, et al. Coffee consumption, gender, and Parkinson's disease mortality in the Cancer Prevention Study-II cohort: the modifying effects of estrogen. Am J Epidemiol. 2004; 160 (10): 977-984.
9. Ascherio A, Zhang SM, Hernàn MA, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol. 2001; 50 (1): 56-63.
10. Benarroch EE. Adenosine and its receptors: multiple modulatory functions and potential therapeutic targets for neurologic disease. Neurology 2008; 70: 231-236.
11. Blum, D., Gall, D., Galas, M.C., d'Alcantara, P., Bantubungi, K, Schiffmann, S. N. The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity. J. Neurosci. 2002; 22: 9122-9133.
12. Canas PM, Porciuncula LO, Cunha GM, Silva CG, Machado NJ, Oliveira JM, Oliveira CR, Cunha RA. Adenosine A2A-receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2009; 29: 14741-51.
13. Cao C, Loewenstein DA, Lin X, Zhang C, Wang L, Duara R, Wu Y, Giannini A, Bai G, Cai J, Greig M, Schofield E, Ashok R, Small B, Potter H, Arendash GW. High Blood caffeine levels in MCI linked to lack of progression to dementia. Journal of Alzheimer's disease: Journal of Alzheimer’s Disease. 2012; 30: 559-72.
14. Carroll JB, Bates GP, Steffan J, et al. Treating the whole body in Huntington's disease. Lancet Neurol 2015; 14: 1135.
15. Chou, S.Y., Lee, Y.C., Chen, H.M., Chiang, M.C., Lai, H.L., Chang, H.H., et al. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J. Neurochem. 2005; 93: 310-320.
16. Ciruela F, Gômez-Soler M, Guidolin D, Borroto-Escuela DO, Agnati LF, Fuxe K, Fernàndez- Duenas V. Adenosine receptor containing oligomers: their role in the control of dopamine and glutamate neurotransmission in the brain. Biochim Biophys Acta. 2011; 1808 (5): 1245-55.
17. Clémence Simonin, Cécile Duru, et al. Association between caffeine intake and age of onset in Huntington’s disease. Neurobiol Dis 2013; 58: 179-182.
18. Cunha GM, Canas PM, Melo CS, Hockemeyer J, Muller CE, Oliveira CR, Cunha RA. Adenosine A2A receptor blockade prevents memory dysfunction caused by beta-amyloid peptides but not by scopolamine or MK-801. Experimental neurology. 2008; 210: 776-81.
19. Cunha RA, Constantino MC, Sebastiao AM, Ribeiro JA. Modification of A1 and A2a adenosine receptor binding in aged striatum, hippocampus and cortex of the rat. Neuroreport. 1995; 6: 1583-8.
20. D. Deleu, P. Jacob, P. Chand, et al. Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease. Neurol. 2006; 67: 897.
21. Dauer W, Przedborski. Parkinson’s disease: mechanisms and models. Neuron 2003; 39: 889-909.
22. Diogenes MJ, Costenla AR, Lopes LV, Jeronimo- Santos A, Sousa VC, Fontinha BM, Ribeiro JA, Sebastiao AM. Enhancement of LTP in aged rats is dependent on endogenous BDNF. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. 2001; 36: 1823-36.
23. Dworak M, Diel P, Voss S, Hollmann W, Struder H.K. Intense exercise increases adenosine concentrations in rat brain: implications for a homeostatic sleep drive. Neurosci 2007; 150: 789-795.
24. EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies). Scientific Opinion on the substantiation of health claims related to caffeine and increased alertness (ID 736, 1101, 1187, 1485, 1491,2063,2103) and increased attention (ID 736, 1485, 1491, 2375) pursuant to Article 13 (1) of Regulation (EC) No 1924/2006. EFSA Journal2011; 9 (4): 2054.
25. Elinor Fondell, Eilis J. O’Relly, et al. Intakes of caffeine, coffee and tea an risk of Amyotrophic Lateral Sclerosis: Results from five cohort studies. Amyotroph Lateral Scler Frontotemporal Degener 2015; 16 (0): 366-371.
26. Eskelinen MH, Ngandu T, Tuomilehto J, Soininen H, Kivipelto M. Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. Journal of Alzheimer's disease. 2009; 16: 85-91.
27. Fatma M Ghoneim, Hanaa A Khalaf, Ayman Z Elsamanoudy, Salwa M Abo El-khair, Ahmed MN Helaly, El-Hassanin M Mahmoud, Saad H Elshafey. Protective effect of chronic caffeine intake on gene expression of brain derived neurotrophic factor signalling and the immunoreactivity of glial fibrillary acidic protein and Ki-67 in Alzheimer’s disease. Int J Clin Exp Pathol. 2015; 8 (7): 7710-7728.
28. Fredholm BB, Chen JF, Cunha RA, Svenningsson P, Vaugeois JM. Adenosine and brain function. Int Rev Neurobiol 2011; 63: 191-270.
29. Fredholm BB, Svenningsson P. Adenosine-dopamine interactions: development of a concept and some comments on therapeutic possibilities. Neurology 2003; 61 (11): 5-9.
30. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson’s disease. J Neurochem 2002; 81: 1285-1297.
31. Hall ED, Oostveen JA, Gurney ME. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 1998; 23:249.
32. Huang, N.K., Lin, J.H., Lin, J.T., Lin, C.I., Liu, E.M., Lin, C.J., et al. A new drug design targeting the adenosinergic system for Huntington's disease. PLoS One 6, e20934. 2011.
33. Ian P. Stolerman, Lawrence H. Price. Encyclopedia of Psychopharmacology. 2015.
34. Joaquim A. Ribeiro, Ana M. Sebastiao. Caffeine and Adenosine. J Alzheimers Dis. 2010; 20: S3-S15.
35. Lindsay J, Laurin D, Verreault R, Hebert R, Helliwell B, Hill GB, McDowell I. Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. American journal of epidemiology. 2002; 156: 445-53.
36. Lopes LV, Cunha RA, Ribeiro JA. Cross talk between A1 and A2A adenosine receptors in the hippocampus and cortex of young adult and old rats. Journal of neurophysiology. 1999; 82: 3196-203.
37. Maia L, de Mendonca A. Does caffeine intake protect from Alzheimer's disease? European journal of neurology: the official journal of the European Federation of Neurological Societies. 2002; 9: 377-82.
38. Meissner WG, Frasier M, Gasser T, et al. Priorities in Parkinson's disease research. Nat Rev Drug Discov. 2015; 10 (5): 377-393.
39. Mievis, S., Blum, D., Ledent, C. A2A receptor knockout worsens survival and motor behaviour in a transgenic mouse model of Huntingtons disease. Neurobiol. Dis. 2011; 41: 570-576.
40. Morano A, Jiménez-Jiménez FJ, Molina JA, Antolin MA. Risk-Factors for Parkinson's disease: case-control study in the province of Cdceres, Spain. Acta Neurol Scand. 1994; 89: 16-4-170.
41. Morley JE, Farr SA. The role of amyloid-beta in the regulation of memory. Biochem Pharmacol. 2014.
42. Natalia Palacios, Xiang Gao, Marjorie L. McCullough, Michael A. Schwarzschild, Roma Shah, Susan Gapstur, Alberto Ascherio. Caffeine and risk of Parkinson disease in a large cohort of men and women. Mov Disord. 2012; 27 (10): 1276-1282.
43. Nehlig A. Is caffeine a cognitive enhancer? J Alzheimers Dis 2010; 20: 85-94.
44. Noschang CG, Krolow R, Pettenuzzo LF, A'vila MC, Fachin A, Arcego D, Toigo EP, Crema LM, Diehl LA, Vendite D, Dalmaz C. Interactions between chronic stress and chronic consumption of caffeine on the enzymatic antioxidant system. Neurochem Res 2009; 34: 1568-1574.
45. Ogata T, Schubert P (1996) Programmed cell death in rat microglia is controlled by extracellular adenosine. Neurosci Lett 218: 91-94.
46. Paganini-Hill A. Risk factors for Parkinson's disease: the leisure world cohort study. Neuroepidemiology. 2001; 20 (2): 118-124.
47. Parvizi J, Anderson SW, Martin CO, et al. Pathological laughter and crying: a link to the cerebellum. Brain 2001; 124: 1708.
48. Popat RA, Van den Eeden SK, Tanner SM, et al. Coffee, ADORA2A and CYP1A2: the caffeine connection in Parkinson’s disease. Eur J Neurol. 2011; 18 (5): 756-765.
49. Potenza, R.L., Armida, M., Ferrante, A., Pèzzola, A., Matteucci, A., Puopolo, M., Popoli, P. Effects of chronic caffeine intake in a mouse model of amyotrophic lateral sclerosis. J. Neurosci. Res. 2013; 91: 585-592.
50. Qin L Liu Y, Cooper C, Liu B, Wilson B, Hon JS. Microglia enhance beta-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. J Neurochem 2002; 83: 973-983.
51. Reyes-Izquierdo, T., Nemzer, B., Shu, C., Huynh, L., Argumedo, R., Keller, R., Pietrzkowski, Z. Modulatory effect of coffee fruit extract on plasma levels of brain-derived neurotrophic factor in healthy subjects. Br. J. Nutr. 2013; 14: 1-6.
52. Ronald B. Postuma, Anthony E. Lang, Renato P. Munhoz, Katia Charland, Amelie Pelletier, Mariana Moscovich, Luciane Filla, Debora Zanatta, Silvia Rios Romenets, Robert Altman, Rosa Chuang, Binit Shah. Caffeine for treatment of Parkinson disease. A randomized controlled trial. Neurology. 2012; 79: 651-658.
53. Ross GW, Abbott RD, Petrovich H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA. 2000; 283 (20): 2674-2679.
54. Rothstein JD, Tsai G, Kuncl RW, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990; 28: 18.
55. Rui Liu, Xuguang Guo, Yikyung Park, Xuemei Huang, Rashmi Sinha, Neal D. Freedman, Albert R. Hollenbeck, Aaron Blair, and Honglei Chen. Caffeine intake, Smoking, and Risk of Parkinson Disease in Men and Women. Am J Epidemiol 2012; 175 (11): 1200-1207.
56. Seliverstov Y. A., Seliverstova E. V., Klyushnikov S. A., Konovalov R. N., Illarioshkin S. N. First experience of performing resting-state functional MRI in Russia: studying controls versus early manifest Huntington’s disease patients. Mov Disord. 2014; 51 (29): 594
57. Shaw PJ, Forrest V, Ince PG, et al. CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration 1995; 4:209.
58. Tan EK, Tan C, Fook-Chong SMC, et al. Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese. J Neurol Sci. 2003; 216: 163-167.
59. Tozzi A, Tscherter A, Belcastro V, Tantucci M, Costa C, Picconi B, Centonze D, Calabresi P, Borsini F. Interaction of A2A adenosine and D 2 dopamine receptors modulates corticostriatal glutamatergic transmission. Neuropharmacology 2007; 53: 783-789.
60. van Gelder BM, Buijsse B, Tijhuis M, Kalmijn S, Giampaoli S, Nissinen A, Kromhout D. Coffee consumption is inversely associated with cognitive decline in elderly European men: the FINE Study. European journal of clinical nutrition. 2007; 61: 226-32.
61. Volterra A, Meldolesi J. Astrocytes, from brain glue to communication elements: the revolution continues. Nature Rev. 2005; Neurosci6:626-640.
62. WalkerFO. Huntington's disease. Lancet2007; 369: 218.
63. Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson’s disease. Brit J Pharmacol 2007; 150: 963-976.
64. Wirdefeldt K, Gatz M, Pawitan Y, Pedersen NL Risk and protective factors for Parkinson's disease: A study in Swedish twins. Ann Neurol. 2005; 57 (1): 27-33.
65. Xu K Bastia E, Schwarzschild M. Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease. Pharmacol Ther. 2005; 105 (3): 267-310.
66. Xu K, Xu Y, Brown-Jermyn D, et al. Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl- 1,2,3,6-tetrahy-dropyridine model of Parkinson's disease. J Neurosci. 2006; (2): 535-541.
67. Young-Seok Kim, Sang Mi Kwak, Seung-Kwon Myung. Caffeine Intake from Coffee or Tea and Cognitive Disorders: A Meta-Analysis of Observational Studies. Neuroepidemiol. 2015; 44: 51-63.
68. Zhang Q, Haydon PG. Roles for gliotransmission in the nervous system. J Neural Transm 2005; 112: 121-125.
Review
For citations:
Selivyorstov Yu.A., Babin M.E. Caffeine and neurodegenerative disorders. Medical alphabet. 2018;2(17):37-42. (In Russ.)
Views:
807
Email this article 